Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0GIBEK
|
|||||
---|---|---|---|---|---|---|
ADC Name |
Mirvetuximab-SMCC-DM1
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 4 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Gestational choriocarcinoma [ICD11:2C75]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
Drug-to-Antibody Ratio |
3.6-3.9
|
|||||
Structure | ||||||
Antibody Name |
Mirvetuximab
|
Antibody Info | ||||
Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
Payload Name |
Mertansine DM1
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
Combination Type |
Emtansine
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | 55.86% (Day 14) | High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell) | ||
Method Description |
Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 25 02 mg/kg, equivalent to 51 3 g conjugated maytansinoid per kg The conjugates were injected on day 7 after cell inoculation.
|
||||
In Vivo Model | FRalpha-positive KB CDX model | ||||
In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | 99.17% (Day 10) | High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell) | ||
Method Description |
Five-week-old female CB-17 severe combined immunodeficient (SCID) mice were obtained and quarantined for 7 days prior to study initiation Mice were inoculated subcutaneously with KB cells (1 x107 cells per mouse) resuspended in serum-free culture mediaMice with established KB xenografts were dosed with a single intravenous injection of 200 g of conjugated maytansinoid per kg, equivalent to 102 mg/kg antibody on day 6 after cell inoculationTumor dimensions were measured twice weekly and volume was calculated as (A B2) 05, where A represents the largest and B the perpendicular tumor diameter.
Click to Show/Hide
|
||||
In Vivo Model | FRalpha-positive KB CDX model | ||||
In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.08±0.01 nM | High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell) | ||
Method Description |
Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.
Click to Show/Hide
|
||||
In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10±0.02 nM | High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell) | ||
Method Description |
Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.
Click to Show/Hide
|
||||
In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7.00±2.00 nM | Moderate FOLR1 expression (FOLR1++; 290,000 FOLR1 molecules/cell) | ||
Method Description |
Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure) Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.
Click to Show/Hide
|
||||
In Vitro Model | Gestational choriocarcinoma | JEG-3 cells | CVCL_0363 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 20.00±0.70 nM | High FOLR1 expression (FOLR1+++; 1,300,000 FOLR1 molecules/cell) | ||
Method Description |
Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.
Click to Show/Hide
|
||||
In Vitro Model | Ovarian endometrioid adenocarcinoma | IGROV-1 cells | CVCL_1304 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.